atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire • 09/14/23
atai Life Sciences N.V. (ATAI) Loses -15.43% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 09/06/23
Atai Life Sciences: RL-007, Targeting Schizophrenia Subpopulation With No FDA Approved TherapiesSeeking Alpha • 09/01/23
Down -24.4% in 4 Weeks, Here's Why You Should You Buy the Dip in atai Life Sciences N.V. (ATAI)Zacks Investment Research • 08/21/23
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)GlobeNewsWire • 08/10/23
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)GlobeNewsWire • 08/08/23
TOMS Shoes founder is pledging $100 million for psychedelic research – Here's why he's doing it.Market Watch • 06/21/23
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and UpdatesGlobeNewsWire • 05/11/23
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual MeetingGlobeNewsWire • 04/28/23
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)GlobeNewsWire • 04/13/23
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline HighlightsGlobeNewsWire • 03/24/23
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care ConferenceGlobeNewsWire • 03/01/23